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Introduction 
Systemic sclerosis (SSc) is a multisystem connective tissue disease of uncertain 
aetiology that is characterised by inflammation and fibrosis in the skin, internal 
organs and vascular abnormalities. Scleroderma is classified according to the pattern 
of skin involvment, including limited cutaneous (lcSSc) and diffuse cutaneous (dcSSc) 
systemic sclerosis(1).  
 
Scleroderma renal crisis (SRC) is the most important renal complication in SSc and is 
characterised by the acute onset of severe hypertension (often described as 
accelerated or malignant) together with acute kidney injury (AKI). It is estimated to 
occur in 10-15 % of patients with dcSSc and very rarely (1-2 %) in lcSSc (2,3). The 
reported median duration of SSc at the time of SRC is 7.5 months (range 0-200 
months) with 66% of patients suffering SRC within one year of diagnosis of SSc (2,4). 
It is unknown why only a minority of patients with SSc develop SRC. A second major 
or multiple minor triggers as well as genetic susceptibility are likely, in addition to 
SSc.  As part of the UK Scleroderma Study Group (UKSSG), we developed guidelines 
on the diagnosis and management of Scleroderma Renal Crisis (SRC) based on best 
available evidence and observational clinical experience. 
 
 
Risk Factors associated with SRC 
 
Major risk factors for the development of SRC include early dcSSc, rapidly 
progressive skin disease, tendon friction rubs, recent high-dose corticosteroid use 
(e.g. prednisolone or equivalent at >15 mg/day) and positive RNA Polymerase III 
(ARA) antibody. In the Australian Scleroderma cohort study, independent of 
corticosteroid exposure, the presence of ARA conferred a 25% risk of developing SRC 
and was measurable in 59 % of SRC patients in one cohort (2,5).  
 
Other risk factors for SRC include hormone replacement therapy (HRT), pericardial 
effusion, cardiac insufficiency, high skin score and large joint contractures (6). 
Anaemia, thrombocytopenia and new cardiac events may arise as early 
consequences of the SRC rather than representing true risk factors yet they serve as 
useful alerts to the possibility of SRC. 
 
To aid early identification of the occurrence of renal crisis in high risk patients we 
recommend home blood pressure monitoring twice weekly for all patients with 
dcSSc who are within 4 years of diagnosis. Blood pressure targets should be 
individualised according to the patients’ own normal BP readings (see below). 
 
Diagnosis of SRC 
 
The diagnosis of SRC is summarised in Table 1. Clinically, SRC is characterised by the 
development of accelerated hypertension together with acute kidney injury. If a 
patient with SSc has an elevated blood pressure (BP) of >150/85 mmHg or an 
increase of ≥20 mmHg from their usual systolic BP on two occasions in 24 hours, 
they should be assessed urgently with blood tests and urinalysis. If there is a 
significant increase in serum creatinine  (either an absolute increase of 26.5 µmol/L 
or  an increase of 50% from the baseline value) or urine dipstick shows proteinuria 
(>2+) and/or haematuria (1+), they should be started on an angiotensin converting 
enzyme inhibitor (ACEi) immediately and admitted to hospital for further 
assessment. 
 
Most patients with renal crisis presenting to clinicians complain of non-specific 
symptoms including fatigue and dyspnoea. Other typical clinical features are those 
seen in accelerated hypertension of any cause: there may be headache, blurred 
vision or other encepholopathic symptoms, including seizures. 
 
In addition to the above there may be evidence of microangiopathic haemolytic 
anaemia (MAHA), oliguria, cardiac failure and tachyarrhythmias.  MAHA or intra-
vascular haemolysis is present in approximately 50% of patients with SRC and is 
evidenced by reduced platelet counts, red cell fragments, reduced serum 
haptoglobin levels, red cell fragments and schistocytes on blood film together with 
massively elevated lactate dehydrogenase (LDH) levels. Echocardiogram will often 
demonstrate a reduced left ventricular ejection fraction and pulmonary oedema is 
common in SRC. However, these findings typically result from dramatically increased 
peripheral resistance and effective outflow tract obstruction rather than primary 
myocardial dysfunction. Tachycardias and tachyarrythmias are also seen in this 
group, which has a high prevalence of concomittant myocardial fibrosis. 
 
Renal biopsy is helpful to resolve diagnostic uncertainty as to the cause of acute 
kidney injury (where there is a positive ANCA screen for example) and also to assess 
renal prognosis. The risk of haemorrhage is increased in the context of uncontrolled 
hypertenison, so biopsy should not be performed until the patient’s BP is well 
controlled, the clinical condition of the patient is stable and the platelet count has 
recovered.  
 
 
Management of SRC 
 
Acute management of SRC involves general supportive care with thoughtful BP 
control (Figure 1). Prompt BP control is essential if hypertensive encephalopathy or 
cardiac de-compensation dictate it. Otherwise, moderate, steady reduction in BP 
(10% reduction in systolic BP per day) is likely to optimise chances of renal recovery. 
The use of an ACEi in the early stages is now standard and there is evidence that 
continuation of these agents even if the patient becomes dialysis dependent 
improves the chances of recovering renal function and becoming dialysis 
independent (7,8). There is no evidence that a short-acting ACEi (e.g. captopril) 
should be preferred to a long-acting agent (e.g. ramipril) unless the patient has 
marked cardiovascular instability. Beta blockers are relatively contraindicated given 
the risk of reducing cardiac output in the face of massively raised peripheral 
resistance. The choice of other agents is largely dependent on patient response. 
 
Angiotensin Receptor Blockers (ARBs) are an alternative where ACEi is not tolerated 
although there is some evidence they may not be as effective (9,10). The use of 
prophylactic ACEi in at risk patients with SSc is not recommended and it may result in 
worse outcomes (11,12). Conventional intra-venous vasodilators (e.g. GTN) are 
effective where rapid reduction in BP is required. Intravenous prostaglandin 
analogues (e.g. Iloprost) also provide effective blood pressure control and may have 
the added advantage of discouraging platelet/vascular endothelial activation. 
 
Around 60% of patients with SRC will progress to requiring renal replacement 
therapy (RRT) at some point, despite appropriate BP management (2,13). The choice 
of RRT is between continuous methods—haemofiltration or peritoneal dialysis 
(PD)—or intermittent haemodialysis (HD). Historically, a large majority of patients 
has been treated with HDdue to the greater availability of this modality. However, 
intravascular instability in the early stages of SRC means that continuous modalities 
may be preferable where available and ptractical for the patient.  
 
For dialysis dependent patients, renal transplantation is an option but careful 
consideration needs to be given to the timing of transplantation as renal recovery 
can occur up to two years following SRC (2). Post-transplant immunosuppression 
needs to be considered carefully as calceneurin inhibitors (ciclosporin and 
tacrolimus) are renal vasoconstrictors associated with an increased risk of SRC 
(14,15). Furthermore, co-existing cardiac and pulmonary disease may dictate 
suitability for listing. Although in general renal transplantation offers superior 
survival in SRC patients (16), graft survival is reduced compared to the general renal 
transplant population and recurrence of scleroderma may play a role in this poor 
post-renal transplant outcome (10,17).  
 
 
Conclusion 
 
Despite recent improvements in overall survival in SSc and advances in organ-based 
therapies, SRC remains an important complication of the disease. An estimated 15 % 
of SSc patients may develop SRC, which presents as acute onset hypertension and 
acute kidney injury. Current strategies to reduce the associated morbidity and 
mortality include identifying at risk patients to aid early diagnosis and ACEi therapy 
should be lifelong in all patients, regardless of whether they require renal 
replacement therapy. Patients with SRC may recover renal function up to 3 years 
after the crisis, most often within 12 to 18 months. Deaths are more frequent in 
patients who do not recover renal function.  
  
Table 1 Diagnosis of scleroderma renal crisis 
 
Diagnostic criteria (essential) 
New onset BP >150/85 mmHg 
or                                                                                    obtained at least twice over 24 hrs 
Increase ≥ 20 mmHg from usual systolic BP 
Acute Kidney Injury stage 1 or higher: 
>50% increase in serum creatinine from stable baseline or an absolute increase of 26.5 
µmol/L) 
Supportive evidence (desirable) 
Microangiopathic haemolytic anaemia on blood film, thrombocytopaenia and other 
biochemical findings consistent with haemolysis 
Findings consistent with accelerated hypertension on retinal examination 
Microscopic haematuria on urine dipstick and/or red blood cells on urine microscopy 
Oliguria or anuria 
Renal biopsy with typical features of SRC including onion skin proliferation within the walls 
of intrarenal arteries and arterioles, fibrinoid necrosis, glomerular shrinkage. 
Flash pulmonary oedema 
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